Anxiety sensitivity means fear of anxiety-related sensations which is one of the important factors in the development and maintenance of substance-related disorders. Studies support the underlying, mediating, and moderating role of this construct in the etiology of substancerelated disorders. This review suggests that anxiety sensitivity can play a role in this group of disorders in different ways, such as fear of body sensations, fear of cognitive dyscontrol, and fear of socially observable anxiety symptoms. Finally, high anxiety sensitivity can interfere with the treatment of substance-related disorders as an underlying vulnerability and increase the likelihood of relapse in this group of people.

Background and objective: Epilepsy is a refractory disease of the nervous system. This article aimed to analyze the global trend of epilepsy research and the contribution of China to this research. Methods: This paper used “epilepsy, seizure, status epilepticus, SUDEP” to retrieve epilepsy-related articles indexed in the Web of Science from 2011 to 2020, classified and analyzed the global epilepsy-related articles. Results: This paper analyzed 65,270 articles on epilepsy research, showing that Epilepsy Behavior and Epilepsy Research were journals with the largest number of articles concerning epilepsy research in the world and China, respectively. The number of published epilepsy-related articles accounts for 5.43% of the global published articles and 3.29% of the published articles in China. The United States Department of Health Human Services and the National Institutes of Health jointly sponsored 15,713 of these articles, ranking first worldwide in the published epilepsy-related articles. Among 5206 articles published in China, 2696 articles (46.42%) were supported by the National Natural Science Foundation of China. Conclusion: This study has reference significance for researchers in this field to understand the 10-year overview of epilepsy researches and formulate future research directions.

Background and objective: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive nerve stimulation technique that has the potential to improve cognitive function. However, there have been few randomized controlled trials (RCTs) that evaluated the effectiveness of rTMS on cognitive function and the relapse in patients with bipolar disorder. Participants and methods: This double-blind parallel RCT will be conducted at The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), China. A total of 74 bipolar disorder patients will be recruited and randomly assigned to a trial group (n = 37) and control group (n = 37). Repetitive transcranial magnetic stimulation and sham repetitive transcranial magnetic stimulation will be applied over the left dorsolateral prefrontal cortex in the trial group and control group, respectively. This trial was designed on March 2, 2017 and was approved by the Ethics Committee of The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), China on April 25, 2017 (approval No. 2017022). Patient recruitment began on July 10, 2017 and will be finished in December 2020. The trial will be completed in December 2021. The protocol version is 1.0. Outcome measures: The primary outcome measure will be the difference between MATRICS Consensus Cognitive Battery scores at post-intervention and at baseline. The secondary outcome measures will be relapse of depressive and/or hypo/mania episode at a one-year follow-up. Discussion: This clinical trial will provide data regarding effectiveness in long-term cognitive function and relapse of mood episode following repetitive transcranial magnetic stimulation in patients with bipolar disorder. Trial registration: This trial had been registered in the ClinicalTrials.gov (identifier: NCT03207048) on July 2, 2017.